-
Chongqing Drug Administration intends to cancel the Youmei Pharmaceuticals Business License
Time of Update: 2021-08-29
On August 6, Youmei Pharmaceuticals terminated its drug business, and upon the application of the enterprise, the Chongqing Drug Administration planned to cancel its Pharmaceutical Business License .
Attached table: the content of the license to be cancelled
-
Procurement of these varieties or selection of proprietary Chinese medicines
Time of Update: 2021-08-29
With centralized procurement of proprietary Chinese medicines, three types of varieties may be selected. Under the trend, how should companies break through and innovate?0101Possible varieties of cen
-
Faith Medicine's AAV gene therapy is approved for clinical treatment of hemophilia B patients
Time of Update: 2021-08-29
BBM-H901 injection is an AAV gene therapy drug developed by Faith Medicine, which aims to introduce human coagulation factor IX (Factor IX, FIX) gene into hemophilia B patients through intravenous administration, thereby improving and maintaining the patient's body for a long time.
-
Hengrui Carrelizumab is approved by the FDA for Phase III clinical trials in the U.S.
Time of Update: 2021-08-29
Article source: Medical Rubik's Cube InfoToday, Hengrui Pharmaceuticals announced that it has received a letter from the US FDA regarding the approval of the use of carrelizumab for injection in combination with famitinib malate capsules for the phase III clinical trial of advanced non-small cell lung cancer .
-
Hutchison Pharmaceuticals and Epizyme cooperate to develop and commercialize TAZVERIK in Greater China
Time of Update: 2021-08-29
Hutchison Medicine will also participate in Epizyme's global registration study of TAZVERIK® combined with R2 in the treatment of second-line follicular lymphoma, the EZH-302 study, and lead the study in Greater China .
-
Innovent announces a license agreement with Synaffix for antibody-conjugated drug technology
Time of Update: 2021-08-29
According to the terms of the agreement, Synaffix will provide the necessary proprietary ADC technologies, including GlycoConnect™, HydraSpace™, and a certain linker-toxin under its toxSYN™ platform, enabling Innovent to quickly develop its own antibody based on its own antibody and have the best in class Potential ADC candidate molecule .
-
Zerro salmon triple seeding technology has succeeded
Time of Update: 2021-08-29
In order to fully guarantee the controllable provenance, the Salmon and Trout Genetic Breeding Innovation Team of the Heilongjiang Fisheries Research Institute has carried out the seed production of the triploid Salmon .
-
Osaikang: ASKC852 Tablets Subsidiary Obtained Clinical Trial Approval Notice
Time of Update: 2021-08-29
On June 28, Osaikang announced that its subsidiary, ASKC852 tablets, has obtained a notice of clinical trial approval.
ASKC852 tablets are innovative drugs registered and classified as category 1, and are brand-new small-molecule immunomodulatory drugs .
-
AstraZeneca's second-generation PARP inhibitor AZD5305 has been applied for clinical application in China
Time of Update: 2021-08-29
Text | pick up shellsOn July 6, the CDE official website showed that the clinical application of AstraZeneca's second-generation PARP (highly selective PARP1) inhibitor AZD5305 has been accepted by the State Food and Drug Administration .
-
New regulations for continuing education of licensed pharmacists are here
Time of Update: 2021-08-29
In accordance with the requirements of the "Draft of Opinions", the pharmacy professional and technical personnel who participate in continuing education through the following methods will be included in the continuing education hours of the year:1.
-
Amgen Flt3xCD3 dual anti-phase I clinical suspension of BCMxCD3 dual anti-phase I clinical recovery
Time of Update: 2021-08-29
In December 2014, Amgen's CD19xCD3 bispecific antibody blinatumomab (blinatumomab; indication for acute lymphoblastic leukemia) was approved by the FDA for marketing, opening a new phase in the development of dual antibodies .
-
Beijing Municipal Medical Insurance Bureau issued a document to clarify the scope of clinical trials and medical insurance payment
Time of Update: 2021-08-29
" Medical Network, August 11, recently, the Beijing Municipal Medical Insurance Bureau issued the "Notice on Further Clarifying the Scope of Medical Insurance Fund Payment for Medical Expenses Related to Drug Clinical Trials", which is the first nationwide to clarify the relationship between clinical research and medical insurance payments .
-
National Medical Insurance Administration: Accelerate the advancement of traditional Chinese medicine and formula particles into centralized procurement
Time of Update: 2021-08-29
4126 of the Fourth Session of the 13th National People's Congress, and received the recommendation made by Representative Lu Qingguo on accelerating the entry of traditional Chinese medicine and formula granules into centralized procurement.
-
In 2021, the second batch of newly-added packaging quantities drug online procurement notice is released!
Time of Update: 2021-08-29
On July 7, 2021, drug information will be pushed to medical institutions through the "Shanghai Pharmaceutical Purchasing Service and Supervision Information System" (hereinafter referred to as the Sunshine Platform), and price negotiation will take effect on July 9 .
-
Lifang Pharmaceutical appointed Ms. Wang Qing as deputy general manager and elected as a non-independent director
Time of Update: 2021-08-28
Wang Qing as a non-independent director of the fourth board of directors.
The term of office is from the date of approval by the company’s general meeting of shareholders to the expiration of the company’s fourth board of directors.
-
Shi Yunzhong, director of Huaheng Biotechnology, resigns, nominates the candidate Mao Jianwen and is appointed as deputy general manager
Time of Update: 2021-08-28
Shi Yunzhong applied for resignation from the position of director of the third board of directors of the company due to personal work reasons .
-
How to prescribe long-term prescription drugs?
Time of Update: 2021-08-28
However, the "Specifications" also clearly emphasized that medical toxic drugs, radioactive drugs, precursor drugs, narcotic drugs, Class I and Class II psychotropic drugs, and antimicrobial drugs (for the treatment of chronic bacterial and fungal infectious diseases such as tuberculosis ) Except medicines), and medicines with special requirements for storage conditions shall not be used for long-term prescriptions .
-
New regulations for long prescriptions!
Time of Update: 2021-08-28
Long-term prescription management practices (Trial) Chapter I General Provisions Article 1 In order to standardize long-term prescription management, promote hierarchical diagnosis and treatment, promote rational drug use, and ensure medical quality and safety, in accordance with the "Practicing Physician Law", "Drug Administration Law", "Medical Institution Management Regulations", "Narcotic Drugs and Psychotropic Drugs Management Regulations" "Prescription Management Measures", "Regulations on Pharmaceutical Affairs of Medical Institutions" and other relevant regulations, formulate this specification .
-
The world's third BTK-PROTAC starts clinical trial
Time of Update: 2021-08-28
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn August 16, BeiGene registered the US Phase I study of BTK protein degradation agent (BTK-PROTAC) BGB-16673 on the American Clinical Network to treat B-cell malignancies.
-
Is Israel's new drug EXO-CD24 the hope of ending the new coronavirus?
Time of Update: 2021-08-28
The main reason for the death of patients with the new coronavirus infection is the strong pulmonary immune response-or cytokine storm .
